MX2016017117A - Conjugados de anticuerpo her2-farmaco. - Google Patents

Conjugados de anticuerpo her2-farmaco.

Info

Publication number
MX2016017117A
MX2016017117A MX2016017117A MX2016017117A MX2016017117A MX 2016017117 A MX2016017117 A MX 2016017117A MX 2016017117 A MX2016017117 A MX 2016017117A MX 2016017117 A MX2016017117 A MX 2016017117A MX 2016017117 A MX2016017117 A MX 2016017117A
Authority
MX
Mexico
Prior art keywords
linker
self
present disclosure
immolative
targeting
Prior art date
Application number
MX2016017117A
Other languages
English (en)
Spanish (es)
Inventor
Huang Chiu-Chen
Lin Rong-Hwa
Lin Shih-Yao
Hsieh Yu-Chi
Hua LEE Shu-
Ying TSAI Yu-
Original Assignee
Abgenomics Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenomics Int Inc filed Critical Abgenomics Int Inc
Publication of MX2016017117A publication Critical patent/MX2016017117A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016017117A 2014-06-20 2015-06-18 Conjugados de anticuerpo her2-farmaco. MX2016017117A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462014912P 2014-06-20 2014-06-20
US201462015661P 2014-06-23 2014-06-23
PCT/US2015/036414 WO2015195904A1 (en) 2014-06-20 2015-06-18 Her2 antibody-drug conjugates

Publications (1)

Publication Number Publication Date
MX2016017117A true MX2016017117A (es) 2018-01-12

Family

ID=54936097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016017117A MX2016017117A (es) 2014-06-20 2015-06-18 Conjugados de anticuerpo her2-farmaco.

Country Status (16)

Country Link
US (1) US20160051695A1 (enExample)
EP (1) EP3157560A4 (enExample)
JP (1) JP2017525755A (enExample)
KR (1) KR20170063507A (enExample)
CN (1) CN106659783A (enExample)
AU (1) AU2015277100A1 (enExample)
BR (1) BR112016029588A2 (enExample)
CA (1) CA2952834A1 (enExample)
IL (1) IL249626A0 (enExample)
MX (1) MX2016017117A (enExample)
PH (1) PH12016502509A1 (enExample)
RU (1) RU2017101331A (enExample)
SG (2) SG10201811124YA (enExample)
TW (1) TW201625315A (enExample)
WO (1) WO2015195904A1 (enExample)
ZA (1) ZA201700306B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130209449A9 (en) 2011-06-13 2013-08-15 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof
PT2935259T (pt) 2012-12-21 2019-04-04 Abgenomics Int Inc Ligantes de autoimolação hidrofílicos e conjugados dos mesmos
AU2015276821A1 (en) 2014-06-20 2017-01-12 Abgenomics International Inc. Anti-folate receptor aplha (FRA) antibody-drug conjugates and methods of using thereof
US10953106B2 (en) * 2015-02-16 2021-03-23 Lonza Ltd Antibodies
LT3313845T (lt) * 2015-06-29 2020-12-10 Immunogen, Inc. Cisteino inžinerijos antikūnų konjugatai
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
EP3394082B1 (en) * 2015-12-21 2020-08-12 Pfizer Inc Purification of antibody drug conjugates using a sodium phosphate gradient
EP3400239B1 (en) 2016-01-08 2021-06-02 AltruBio Inc. Tetravalent anti-psgl-1 antibodies and uses thereof
CN107029244B (zh) * 2016-02-04 2021-04-27 浙江昭华生物医药有限公司 抗her2抗体-药物偶联物及其应用
KR102697394B1 (ko) * 2017-02-28 2024-08-20 씨젠 인크. 컨쥬게이션을 위한 시스테인 변이된 항체
EP4011396A1 (en) 2017-03-10 2022-06-15 QuiaPEG Pharmaceuticals AB Releasable conjugates
CA3066920C (en) * 2017-06-16 2024-07-02 Lilly Co Eli COMPOUNDS OF MODIFIED ANTIBODY AND CONJUGATES OF THESE
SG10201801219VA (en) 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
WO2019171358A1 (en) * 2018-03-09 2019-09-12 Quiapeg Pharmaceuticals Ab Releasable antibody conjugates
WO2020029982A1 (en) * 2018-08-08 2020-02-13 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd Recombinant bifunctional protein targeting cd47 and her2
EP3849538A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
TWI834720B (zh) 2018-09-12 2024-03-11 瑞典商奎亞培格製藥公司 可釋放glp-1共軛物
CN113891893A (zh) * 2019-03-22 2022-01-04 加利福尼亚大学董事会 用于修饰靶分子的组合物和方法
CA3169792A1 (en) * 2020-03-05 2021-09-10 Umc Utrecht Holding B.V. Membrane ubiquitin ligases to target protein degradation
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
CN112618726B (zh) * 2020-12-21 2022-11-11 江南大学 一种抗体缀合物、增强抗体分子免疫效应功能的方法
KR20230158005A (ko) 2021-03-18 2023-11-17 씨젠 인크. 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출
AU2024256916A1 (en) 2023-04-18 2025-12-04 Astrazeneca Ab Conjugates comprising cleavable linkers
TW202519268A (zh) * 2023-09-11 2025-05-16 美商卡蒂那生物科學股份有限公司 多肽結合組合物及使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2456325T3 (es) * 2003-11-06 2014-04-22 Seattle Genetics, Inc. Compuestos de monometilvalina capaces de conjugación con ligandos
ES2549077T3 (es) * 2004-04-07 2015-10-22 Genentech, Inc. Espectrometría de masas de conjugados de anticuerpos
CA2754531A1 (en) * 2009-03-06 2010-09-30 Seattle Genetics, Inc. Antibody drug conjugates (adc) that bind to 24p4c12 proteins
AU2010270979B2 (en) * 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
CN102933236B (zh) * 2010-04-15 2014-10-08 斯皮罗根有限公司 吡咯并苯二氮卓类及其结合物
PT3056203T (pt) * 2010-04-21 2018-02-15 Syntarga Bv Conjugados de análogos de cc-1065 e ligantes bifuncionais
CN103566377A (zh) * 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
PT2935259T (pt) * 2012-12-21 2019-04-04 Abgenomics Int Inc Ligantes de autoimolação hidrofílicos e conjugados dos mesmos
KR102626525B1 (ko) * 2013-02-08 2024-01-19 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
WO2015104385A2 (en) * 2014-01-10 2015-07-16 Synthon Biopharmaceuticals B.V. Duocarmycin adcs showing improved in vivo antitumor activity

Also Published As

Publication number Publication date
RU2017101331A3 (enExample) 2019-01-31
US20160051695A1 (en) 2016-02-25
WO2015195904A1 (en) 2015-12-23
CN106659783A (zh) 2017-05-10
TW201625315A (zh) 2016-07-16
PH12016502509A1 (en) 2017-04-10
SG11201610468XA (en) 2017-01-27
EP3157560A4 (en) 2018-02-21
ZA201700306B (en) 2019-06-26
CA2952834A1 (en) 2015-12-23
KR20170063507A (ko) 2017-06-08
RU2017101331A (ru) 2018-07-23
EP3157560A1 (en) 2017-04-26
AU2015277100A1 (en) 2017-02-02
BR112016029588A2 (pt) 2017-08-22
JP2017525755A (ja) 2017-09-07
IL249626A0 (en) 2017-02-28
SG10201811124YA (en) 2019-01-30

Similar Documents

Publication Publication Date Title
PH12016502509A1 (en) Her2 antibody-drug conjugates
PH12015501422A1 (en) Hydrophilic self-immolative linkers and conjugates thereof
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
MX2024002632A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
NZ725131A (en) Tubulysin derivatives
PH12016502524A1 (en) Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
PE20181292A1 (es) Conjugados anticuerpo anti-dll3-farmaco y metodos de uso
EP4501352A3 (en) Compositions and methods for car t cell therapy
PH12016500246A1 (en) 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
MX340090B (es) Analogos de spliceostatina.
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
MY170719A (en) Antibody-drug conjugates
NZ720743A (en) Peptidomimetic compounds and antibody-drug conjugates thereof
MX2016007865A (es) Peptidos citotoxicos y conjugados de los mismos.
PH12014501039B1 (en) Cytotoxic peptides and antibody drug conjugates thereof
PH12015500977A1 (en) Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates
MX2013005046A (es) Agentes citotoxicos que comprenden nuevos derivados de ansamitocina.
TW201613641A (en) Anti-CD22 antibody-drug conjugates and methods of using thereof
MX372912B (es) Conjugado farmaco-anticuerpo igf-1r y su uso para el tratamiento contra el cancer.
MX2016007578A (es) Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
WO2019108685A8 (en) Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
AR102506A1 (es) Conjugados de anticuerpo anti-receptor del factor de crecimiento epidérmico 2 humano (her2)-fármaco
HK1236958A1 (en) Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
EP4212181A3 (en) Methylene carbamate linkers for use with targeted-drug conjugates